{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:08:09Z","timestamp":1782140889587,"version":"3.54.5"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National High level Hospital Clinical Research Funding","award":["2023-GSP-RC-09"],"award-info":[{"award-number":["2023-GSP-RC-09"]}]},{"name":"the National High level Hospital Clinical Research Funding","award":["2023-GSP-QN-8"],"award-info":[{"award-number":["2023-GSP-QN-8"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-008"],"award-info":[{"award-number":["2021-I2M-1-008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40265-025-02167-z","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:08:21Z","timestamp":1743703701000},"page":"627-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review"],"prefix":"10.1007","volume":"85","author":[{"given":"Hui-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2167_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.010","volume":"329","author":"H Drexel","year":"2021","unstructured":"Drexel H, Larcher B, Mader A, Vonbank A, Heinzle CF, Moser B, et al. The LDL-C\/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis. 2021;329:44\u20139.","journal-title":"Atherosclerosis"},{"key":"2167_CR2","doi-asserted-by":"publisher","first-page":"1389106","DOI":"10.3389\/fcvm.2024.1389106","volume":"11","author":"B Bashir","year":"2024","unstructured":"Bashir B, Schofield J, Downie P, France M, Ashcroft DM, Wright AK, et al. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia. Front Cardiovasc Med. 2024;11:1389106.","journal-title":"Front Cardiovasc Med."},{"issue":"10263","key":"2167_CR3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","volume":"396","author":"MB Mortensen","year":"2020","unstructured":"Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644\u201352.","journal-title":"Lancet"},{"key":"2167_CR4","doi-asserted-by":"crossref","unstructured":"Jeong SM, Choi S, Kim K, Kim SM, Lee G, Park SY, et al. Effect of change in total cholesterol levels on cardiovascular disease among young adults. J Am Heart Assoc. 2018;7(12):e008819.","DOI":"10.1161\/JAHA.118.008819"},{"issue":"11","key":"2167_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012924","volume":"8","author":"SS Gidding","year":"2019","unstructured":"Gidding SS, Allen NB. Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem. J Am Heart Assoc. 2019;8(11): e012924.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2167_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/2396987319838100","volume":"4","author":"P Amarenco","year":"2019","unstructured":"Amarenco P, Kim JS, Labreuche J, Giroud M, Lee BC, Mahagne MH, et al. Treat stroke to target trial design: first trial comparing two LDL targets in patients with atherothrombotic strokes. Eur Stroke J. 2019;4(3):271\u201380.","journal-title":"Eur Stroke J"},{"issue":"2","key":"2167_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5853\/jos.2021.01249","volume":"23","author":"JS Kim","year":"2021","unstructured":"Kim JS. Role of blood lipid levels and lipid-lowering therapy in stroke patients with different levels of cerebral artery diseases: reconsidering recent stroke guidelines. J Stroke. 2021;23(2):149\u201361.","journal-title":"J Stroke"},{"key":"2167_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","volume":"319","author":"D Atar","year":"2021","unstructured":"Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, et al. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021;319:51\u201361.","journal-title":"Atherosclerosis"},{"issue":"12","key":"2167_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","volume":"11","author":"KA Krychtiuk","year":"2022","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939\u201349.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"7","key":"2167_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3949\/ccjm.88a.20165","volume":"88","author":"O Mesi","year":"2021","unstructured":"Mesi O, Lin C, Ahmed H, Cho LS. Statin intolerance and new lipid-lowering treatments. Cleve Clin J Med. 2021;88(7):381\u20137.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2167_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","volume":"18","author":"PP Toth","year":"2018","unstructured":"Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, et al. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018;18(3):157\u201373.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"2167_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s12020-022-03263-w","volume":"79","author":"A Meza-Contreras","year":"2023","unstructured":"Meza-Contreras A, Wenczenovicz C, Ruiz-Arellanos K, Vesely EAK, Mogollon R, Montori VM. Statin intolerance management: a systematic review. Endocrine. 2023;79(3):430\u20136.","journal-title":"Endocrine"},{"issue":"9","key":"2167_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15337","volume":"27","author":"M Shah","year":"2024","unstructured":"Shah M, Shrestha K, Tseng CW, Goyal A, Liewluck T, Gupta L. Statin-associated muscle symptoms: a comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies. Int J Rheum Dis. 2024;27(9): e15337.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2167_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","volume":"17","author":"BA Warden","year":"2023","unstructured":"Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19\u201339.","journal-title":"J Clin Lipidol"},{"key":"2167_CR15","doi-asserted-by":"crossref","unstructured":"HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279\u201391.","DOI":"10.1093\/eurheartj\/eht055"},{"issue":"1","key":"2167_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/clc.23935","volume":"46","author":"NR Desai","year":"2023","unstructured":"Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13\u201321.","journal-title":"Clin Cardiol"},{"issue":"8","key":"2167_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752\u201362.","journal-title":"Postgrad Med"},{"issue":"1","key":"2167_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13.","journal-title":"Signal Transduct Target Ther"},{"key":"2167_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100130","volume":"62","author":"NG Seidah","year":"2021","unstructured":"Seidah NG. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer. J Lipid Res. 2021;62: 100130.","journal-title":"J Lipid Res"},{"issue":"3","key":"2167_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40292-019-00323-7","volume":"26","author":"R Del Pinto","year":"2019","unstructured":"Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. low density lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: potential role of PCSK9 inhibitors. High Blood Press Cardiovasc Prev. 2019;26(3):199\u2013207.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"1","key":"2167_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jacl.2017.10.003","volume":"12","author":"J Girona","year":"2018","unstructured":"Girona J, Rodr\u00edguez-Borjabad C, Ibarretxe D, Heras M, Amigo N, Feliu A, et al. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin\/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. J Clin Lipidol. 2018;12(1):211\u20138.","journal-title":"J Clin Lipidol"},{"key":"2167_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-981-15-6082-8_9","volume":"1276","author":"S Guo","year":"2020","unstructured":"Guo S, Xia XD, Gu HM, Zhang DW. Proprotein convertase subtilisin\/kexin-type 9 and lipid metabolism. Adv Exp Med Biol. 2020;1276:137\u201356.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"2167_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2174\/1389450120666190214141626","volume":"20","author":"X Lu","year":"2019","unstructured":"Lu X. Structure and function of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in hyperlipidemia and atherosclerosis. Curr Drug Targets. 2019;20(10):1029\u201340.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"2167_CR24","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s12325-020-01259-4","volume":"37","author":"G Mu","year":"2020","unstructured":"Mu G, Xiang Q, Zhou S, Liu Z, Qi L, Jiang J, et al. Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials. Adv Ther. 2020;37(4):1496\u2013521.","journal-title":"Adv Ther"},{"issue":"12","key":"2167_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","volume":"23","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Catapano AL, Norata GD. Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors. Curr Atheroscler Rep. 2021;23(12):79.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"2167_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/00015385.2023.2256182","volume":"79","author":"M Snel","year":"2024","unstructured":"Snel M, Descamps OS. Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium. Acta Cardiol. 2024;79(3):311\u20138.","journal-title":"Acta Cardiol"},{"key":"2167_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.atherosclerosis.2020.07.006","volume":"308","author":"A Pasta","year":"2020","unstructured":"Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies. Atherosclerosis. 2020;308:6\u201314.","journal-title":"Atherosclerosis"},{"issue":"878","key":"2167_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173114","volume":"5","author":"E Gallego-Colon","year":"2020","unstructured":"Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020;5(878): 173114.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"2167_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/14779072.2018.1497975","volume":"16","author":"G Fitzgerald","year":"2018","unstructured":"Fitzgerald G, Kiernan T. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Rev Cardiovasc Ther. 2018;16(8):567\u201378.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"2167_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jacasi.2023.06.002","volume":"3","author":"JJ Li","year":"2023","unstructured":"Li JJ. Tafolecimab, a novel member of PCSK9 monoclonal antibodies, is worth expecting in a Chinese population. JACC Asia. 2023;3(4):646\u20138.","journal-title":"JACC Asia."},{"key":"2167_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.839571","volume":"9","author":"L Bi","year":"2022","unstructured":"Bi L, Yi J, Wu C, Hu S, Zhang X, Lu J, et al. Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China. Front Cardiovasc Med. 2022;9: 839571.","journal-title":"Front Cardiovasc Med."},{"key":"2167_CR32","doi-asserted-by":"crossref","unstructured":"Lu Y, Wang P, Zhou T, Lu J, Spatz ES, Nasir K, et al. Comparison of prevalence, awareness, treatment, and control of cardiovascular risk factors in China and the United States. J Am Heart Assoc. 2018;7(3):e007462.","DOI":"10.1161\/JAHA.117.007462"},{"issue":"11","key":"2167_CR33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurjpc\/zwad030","volume":"30","author":"S Sawant","year":"2023","unstructured":"Sawant S, Wang N. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023;30(11):1120\u201331.","journal-title":"Eur J Prev Cardiol"},{"key":"2167_CR34","volume":"7","author":"K Xie","year":"2024","unstructured":"Xie K, Li Y. Could Lipoprotein(a) be a new target for lipid-lowering therapy? Chin Video J Cardiol. 2024;7: e1000165(2024\u201106\u201121).","journal-title":"Chin Video J Cardiol."},{"issue":"3","key":"2167_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacasi.2021.09.002","volume":"1","author":"Y Cui","year":"2021","unstructured":"Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, et al. A potential long-acting LDL-cholesterol-lowering PCSK9 monoclonal antibody: randomized, placebo-controlled phase 1 studies. JACC Asia. 2021;1(3):411\u20135.","journal-title":"JACC Asia."},{"issue":"5","key":"2167_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40256-024-00654-4","volume":"24","author":"E Fatima","year":"2024","unstructured":"Fatima E, Qureshi Z, Khanzada M, Safi A, Rehman OU, Altaf F. The Efficacy of tafolecimab in chinese patients with hypercholesterolemia: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2024;24(5):641\u201350.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"2167_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s11883-024-01228-0","volume":"26","author":"P Jamadade","year":"2024","unstructured":"Jamadade P, Nupur N, Maharana KC, Singh S. Therapeutic monoclonal antibodies for metabolic disorders: major advancements and future perspectives. Curr Atheroscler Rep. 2024;26(10):549\u201371.","journal-title":"Curr Atheroscler Rep"},{"key":"2167_CR38","volume":"41","author":"Y Huo","year":"2023","unstructured":"Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu D, et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac. 2023;41: 100907.","journal-title":"Lancet Reg Health West Pac."},{"issue":"1","key":"2167_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12916-023-02797-8","volume":"21","author":"M Chai","year":"2023","unstructured":"Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77.","journal-title":"BMC Med"},{"issue":"4","key":"2167_CR40","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","volume":"3","author":"L Qi","year":"2023","unstructured":"Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, et al. Tafolecimab in chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial. JACC Asia. 2023;3(4):636\u201345.","journal-title":"JACC Asia."},{"issue":"1","key":"2167_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12934-018-0881-3","volume":"17","author":"D K\u00f6nning","year":"2018","unstructured":"K\u00f6nning D, Kolmar H. Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display. Microb Cell Fact. 2018;17(1):32.","journal-title":"Microb Cell Fact"},{"issue":"1","key":"2167_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41598-018-37212-3","volume":"9","author":"T Ucha\u0144ski","year":"2019","unstructured":"Ucha\u0144ski T, Z\u00f6gg T, Yin J, Yuan D, Wohlk\u00f6nig A, Fischer B, et al. An improved yeast surface display platform for the screening of nanobody immune libraries. Sci Rep. 2019;9(1):382.","journal-title":"Sci Rep"},{"key":"2167_CR43","first-page":"1","volume":"13","author":"L Xu","year":"2024","unstructured":"Xu L, Bai X, Joong OhE. Strategic approaches for designing yeast strains as protein secretion and display platforms. Crit Rev Biotechnol. 2024;13:1\u201318.","journal-title":"Crit Rev Biotechnol"},{"key":"2167_CR44","doi-asserted-by":"crossref","unstructured":"Lopez-Morales J, Vanella R, Appelt EA, Whillock S, Paulk AM, Shusta EV, et al. Protein engineering and high-throughput screening by yeast surface display: survey of current methods. Small Sci. 2023;3(12):2300095.","DOI":"10.1002\/smsc.202300095"},{"key":"2167_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.actbio.2020.05.004","volume":"112","author":"K Bacon","year":"2020","unstructured":"Bacon K, Lavoie A, Rao BM, Daniele M, Menegatti S. Past, present, and future of affinity-based cell separation technologies. Acta Biomater. 2020;112:29\u201351.","journal-title":"Acta Biomater"},{"key":"2167_CR46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-4939-9853-1_14","volume":"2070","author":"A Kaempffe","year":"2020","unstructured":"Kaempffe A, J\u00e4ger S, K\u00f6nning D, Kolmar H, Schr\u00f6ter C. Isolation of tailor-made antibody fragments from yeast-displayed B-cell receptor repertoires by multiparameter fluorescence-activated cell sorting. Methods Mol Biol. 2020;2070:249\u201366.","journal-title":"Methods Mol Biol"},{"key":"2167_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.sbi.2018.04.006","volume":"51","author":"T Hattori","year":"2018","unstructured":"Hattori T, Koide S. Next-generation antibodies for post-translational modifications. Curr Opin Struct Biol. 2018;51:141\u20138.","journal-title":"Curr Opin Struct Biol"},{"issue":"8","key":"2167_CR48","doi-asserted-by":"publisher","first-page":"164","DOI":"10.15698\/mic2021.08.756","volume":"8","author":"CS Moesslacher","year":"2021","unstructured":"Moesslacher CS, Kohlmayr JM, Stelzl U. Exploring absent protein function in yeast: assaying post translational modification and human genetic variation. Microb Cell. 2021;8(8):164\u201383.","journal-title":"Microb Cell"},{"issue":"1","key":"2167_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/imr.12409","volume":"270","author":"IN Foltz","year":"2016","unstructured":"Foltz IN, Gunasekaran K, King CT. Discovery and bio-optimization of human antibody therapeutics using the XenoMouse\u00ae transgenic mouse platform. Immunol Rev. 2016;270(1):51\u201364.","journal-title":"Immunol Rev"},{"issue":"3","key":"2167_CR50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1128\/CVI.05589-11","volume":"19","author":"C Tkaczyk","year":"2012","unstructured":"Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, et al. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol. 2012;19(3):377\u201385.","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"2167_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/17460441.2020.1704728","volume":"15","author":"E Khoury","year":"2020","unstructured":"Khoury E, Brisson D, Gaudet D. Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opin Drug Discov. 2020;15(4):403\u201314.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"2167_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","volume":"27","author":"M Khoshnejad","year":"2019","unstructured":"Khoshnejad M, Patel A, Wojtak K, Kudchodkar SB, Humeau L, Lyssenko NN, et al. Development of novel DNA-encoded PCSK9 monoclonal antibodies as lipid-lowering therapeutics. Mol Ther. 2019;27(1):188\u201399.","journal-title":"Mol Ther"},{"issue":"7","key":"2167_CR53","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708662","volume":"12","author":"R Stripecke","year":"2020","unstructured":"Stripecke R, M\u00fcnz C, Schuringa JJ, Bissig KD, Soper B, Meeham T, et al. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol Med. 2020;12(7): e8662.","journal-title":"EMBO Mol Med"},{"issue":"10","key":"2167_CR54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-animal-020420-033029","volume":"15","author":"W Ye","year":"2022","unstructured":"Ye W, Chen Q. Potential applications and perspectives of humanized mouse models. Annu Rev Anim Biosci. 2022;15(10):395\u2013417.","journal-title":"Annu Rev Anim Biosci."},{"key":"2167_CR55","doi-asserted-by":"crossref","unstructured":"Mokhtary P, Pourhashem Z, Mehrizi AA, Sala C, Rappuoli R. Recent progress in the discovery and development of monoclonal antibodies against viral infections. Biomedicines. 2022;10(8):1861.","DOI":"10.3390\/biomedicines10081861"},{"issue":"1","key":"2167_CR56","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"H Kaplon","year":"2023","unstructured":"Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410.","journal-title":"MAbs"},{"issue":"5","key":"2167_CR57","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1097\/MS9.0000000000001945","volume":"86","author":"Z Qureshi","year":"2024","unstructured":"Qureshi Z, Khanzada M, Safi A, Fatima E, Altaf F, Vittorio TJ. Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies. Ann Med Surg (Lond). 2024;86(5):2818\u201327.","journal-title":"Ann Med Surg (Lond)."},{"key":"2167_CR58","doi-asserted-by":"publisher","first-page":"1395854","DOI":"10.3389\/fimmu.2024.1395854","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen YL, Xu H, Rana GE, Tan X, He M, et al. Comparison of \u201cframework Shuffling\u201d and \u201cCDR Grafting\u201d in humanization of a PD-1 murine antibody. Front Immunol. 2024;15:1395854.","journal-title":"Front Immunol"},{"key":"2167_CR59","doi-asserted-by":"crossref","unstructured":"Bai Z, Xu M, Mei Y, Hu T, Zhang P, Chen M, et al. Generation of a novel high-affinity antibody binding to PCSK9 catalytic domain with slow dissociation rate by CDR-grafting, alanine scanning and saturated site-directed mutagenesis for favorably treating hypercholesterolemia. Biomedicines. 2021;9(12):1783.","DOI":"10.3390\/biomedicines9121783"},{"issue":"1","key":"2167_CR60","doi-asserted-by":"publisher","first-page":"1829335","DOI":"10.1080\/19420862.2020.1829335","volume":"12","author":"MR Dyson","year":"2020","unstructured":"Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12(1):1829335.","journal-title":"MAbs"},{"issue":"1","key":"2167_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12944-023-01848-6","volume":"22","author":"S Lin","year":"2023","unstructured":"Lin S, Hu T, Wang K, Wang J, Zhu Y, Chen X. In vitro assessment of the pathogenicity of the LDLR c.2160delC variant in familial hypercholesterolemia. Lipids Health Dis. 2023;22(1):77.","journal-title":"Lipids Health Dis"},{"key":"2167_CR62","doi-asserted-by":"crossref","unstructured":"Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody structure and function: the basis for engineering therapeutics. Antibodies (Basel). 2019;8(4):55.","DOI":"10.3390\/antib8040055"},{"issue":"594","key":"2167_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120164","volume":"1","author":"SC Carrara","year":"2021","unstructured":"Carrara SC, Ulitzka M, Grzeschik J, Kornmann H, Hock B, Kolmar H. From cell line development to the formulated drug product: the art of manufacturing therapeutic monoclonal antibodies. Int J Pharm. 2021;1(594): 120164.","journal-title":"Int J Pharm"},{"issue":"12","key":"2167_CR64","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1111\/cts.13674","volume":"16","author":"S Yan","year":"2023","unstructured":"Yan S, Zhao X, Xie Q, Du W, Ma Q, Zhu T, et al. Pharmacokinetic\/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies. Clin Transl Sci. 2023;16(12):2791\u2013803.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"2167_CR65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10928-018-9592-y","volume":"45","author":"M Kuchimanchi","year":"2018","unstructured":"Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, et al. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018;45(3):505\u201322.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"2167_CR66","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40256-020-00394-1","volume":"20","author":"H Li","year":"2020","unstructured":"Li H, Wei Y, Yang Z, Zhang S, Xu X, Shuai M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of alirocumab in healthy Chinese subjects: a randomized, double-blind, placebo-controlled, ascending single-dose study. Am J Cardiovasc Drugs. 2020;20(5):489\u2013503.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"2167_CR67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/jcph.840","volume":"57","author":"JP Gibbs","year":"2017","unstructured":"Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, et al. Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9 (PCSK9). J Clin Pharmacol. 2017;57(5):616\u201326.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"2167_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","volume":"57","author":"S Kasichayanula","year":"2018","unstructured":"Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57(7):769\u201379.","journal-title":"Clin Pharmacokinet"},{"key":"2167_CR69","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.2147\/DDDT.S493912","volume":"18","author":"J Li","year":"2024","unstructured":"Li J, Huang S, Hu X, Chen J. Comprehensive assessment of PCSK9 inhibitors for lipid management: scientific guidance based on drug selection recommendations for Chinese Medical Institutions. Drug Des Devel Ther. 2024;18:6297\u2013312.","journal-title":"Drug Des Devel Ther."},{"issue":"16","key":"2167_CR70","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s40265-023-01952-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Tafolecimab: First Approval. Drugs. 2023;83(16):1545\u20139.","journal-title":"Drugs"},{"issue":"3","key":"2167_CR71","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ehjcvp\/pvae013","volume":"10","author":"J Tamargo","year":"2024","unstructured":"Tamargo J, Agewall S, Borghi C, Ceconi C, Cerbai E, Dan GA, et al. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. Eur Heart J Cardiovasc Pharmacother. 2024;10(3):219\u201344.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"2167_CR72","doi-asserted-by":"crossref","unstructured":"de Oliveira LLH, de Assis ACR, Giraldez VZR, Scudeler TL, Soares PR. Dyslipidemia: A narrative review on pharmacotherapy. Pharmaceuticals (Basel). 2024;17(3):289.","DOI":"10.3390\/ph17030289"},{"key":"2167_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2022.03.027","volume":"350","author":"H Teng","year":"2022","unstructured":"Teng H, Gao Y, Wu C, Zhang H, Zheng X, Lu J, et al. Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35\u201375 years: results from China PEACE Million Persons Project. Atherosclerosis. 2022;350:58\u201364.","journal-title":"Atherosclerosis"},{"issue":"3","key":"2167_CR74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jacl.2022.03.003","volume":"16","author":"L Jiang","year":"2022","unstructured":"Jiang L, Stoekenbroek RM, Zhang F, Wang Q, Yu W, Yuan H, et al. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study. J Clin Lipidol. 2022;16(3):306\u201314.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2167_CR75","doi-asserted-by":"publisher","first-page":"bvaa122","DOI":"10.1210\/jendso\/bvaa122","volume":"5","author":"DTW Lui","year":"2021","unstructured":"Lui DTW, Lee ACH, Tan KCB. Management of Familial Hypercholesterolemia: Current Status and Future Perspectives. J Endocr Soc. 2021;5(1):bvaa122.","journal-title":"J Endocr Soc."},{"key":"2167_CR76","doi-asserted-by":"publisher","first-page":"1454918","DOI":"10.3389\/fcvm.2024.1454918","volume":"11","author":"D Liu","year":"2024","unstructured":"Liu D, Zhang J, Zhang X, Jiang F, Wu Y, Yang B, et al. The efficacy and safety of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis. Front Cardiovasc Med. 2024;11:1454918.","journal-title":"Front Cardiovasc Med."},{"issue":"1","key":"2167_CR77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/joim.12981","volume":"287","author":"A Vuorio","year":"2020","unstructured":"Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287(1):2\u201318.","journal-title":"J Intern Med"},{"issue":"4","key":"2167_CR78","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","volume":"14","author":"EE Brown","year":"2020","unstructured":"Brown EE, Sturm AC, Cuchel M, Braun LT, Duell PB, Underberg JA, et al. Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. J Clin Lipidol. 2020;14(4):398\u2013413.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2167_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101719","volume":"37","author":"AJ Berberich","year":"2023","unstructured":"Berberich AJ, Hegele RA. The advantages and pitfalls of genetic analysis in the diagnosis and management of lipid disorders. Best Pract Res Clin Endocrinol Metab. 2023;37(3): 101719.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2167_CR80","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/17425255.2020.1802426","volume":"16","author":"JJ Li","year":"2020","unstructured":"Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol. 2020;16(9):837\u201351.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"2167_CR81","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.3213","volume":"115","author":"JJ Li","year":"2024","unstructured":"Li JJ, Dou KF, Zhou ZG, Zhao D, Ye P, Chen H, et al. Chinese expert consensus on the clinical diagnosis and management of statin intolerance. Clin Pharmacol Ther. 2024;115(5):954\u201364.","journal-title":"Clin Pharmacol Ther"},{"key":"2167_CR82","doi-asserted-by":"crossref","unstructured":"Mansfield BS, Mohamed F, Larouche M, Raal FJ. The hurdle of access to emerging therapies and potential solutions in the management of dyslipidemias. J Clin Med. 2024;13(14):4160.","DOI":"10.3390\/jcm13144160"},{"issue":"260","key":"2167_CR83","first-page":"196","volume":"1","author":"M Zhang","year":"2018","unstructured":"Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol. 2018;1(260):196\u2013203.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2167_CR84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12963-019-0197-5","volume":"17","author":"REK Man","year":"2019","unstructured":"Man REK, Gan AHW, Fenwick EK, Gan ATL, Gupta P, Sabanayagam C, et al. Prevalence, determinants and association of unawareness of diabetes, hypertension and hypercholesterolemia with poor disease control in a multi-ethnic Asian population without cardiovascular disease. Popul Health Metr. 2019;17(1):17.","journal-title":"Popul Health Metr"},{"key":"2167_CR85","doi-asserted-by":"publisher","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2024;zwae281. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281. Online ahead of print.","DOI":"10.1093\/eurjpc\/zwae281"},{"issue":"7","key":"2167_CR86","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/HJH.0000000000003699","volume":"42","author":"SV Moreno","year":"2024","unstructured":"Moreno SV, Grimes C, Bolton KA, Uddin R, Siopis G, Maddison R, et al. The burden of cardiovascular disease attributable to high dietary sodium intake in Australia between 1990 and 2019. J Hypertens. 2024;42(7):1163\u201372.","journal-title":"J Hypertens"},{"issue":"8","key":"2167_CR87","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","volume":"2","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries. JAMA Cardiol. 2017;2(8):890\u20135.","journal-title":"JAMA Cardiol."},{"key":"2167_CR88","doi-asserted-by":"publisher","unstructured":"P\u00f6rschmann T, Meier T, Lorkowski S. Cardiovascular mortality attributable to dietary risk factors in 54 countries in the WHO European Region from 1990 to 2019: an updated systematic analysis of the Global Burden of Disease Study. Eur J Prev Cardiol. 2024;zwae136. https:\/\/doi.org\/10.1093\/eurjpc\/zwae136. Online ahead of print.","DOI":"10.1093\/eurjpc\/zwae136"},{"issue":"5","key":"2167_CR89","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s11739-024-03605-8","volume":"19","author":"R Li","year":"2024","unstructured":"Li R, Shao J, Hu C, Xu T, Zhou J, Zhang J, et al. Metabolic risks remain a serious threat to cardiovascular disease: findings from the Global Burden of Disease Study 2019. Intern Emerg Med. 2024;19(5):1299\u2013312.","journal-title":"Intern Emerg Med"},{"issue":"3","key":"2167_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102341","volume":"49","author":"L Alhuneafat","year":"2024","unstructured":"Alhuneafat L, Ta\u2019ani OA, Jabri A, Tarawneh T, ElHamdan A, Naser A, et al. Cardiovascular disease burden in the Middle East and North Africa region. Curr Probl Cardiol. 2024;49(3): 102341.","journal-title":"Curr Probl Cardiol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02167-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:04:22Z","timestamp":1745575462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02167-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02167-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"23 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was partially supported by the National High level Hospital Clinical Research Funding [2023-GSP-RC-09; 2023-GSP-QN-8] and CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I2M-1-008]. The funding sources were not involved in the manuscript\u2019s preparation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hui-Hui Liu, Sha Li, and Jian-Jun Li declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Hui-Hui Liu and Sha Li searched and summarized previous studies, collected, analyzed, and interpreted data, and drafted the original manuscript. Jian-Jun Li developed the idea, directed and supervised the analysis, and made critical revisions to the manuscript. All authors declare that they take responsibility for the contents of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated for this narrative review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}